Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045657 | 0.85 | NPSR1 (0.48) | NPSR1MAPK1MAPTMTORALDH1A1 | |
| SCHEMBL7046842 | 0.80 | MAPK1 (0.48) | NPSR1MAPK1MAPTMTORALDH1A1 | |
| SCHEMBL3399374 | 0.79 | MTOR (0.44) | NPSR1MAPK1MAPTMTORALDH1A1 | |
| SCHEMBL3399370 | 0.79 | MTOR (0.44) | NPSR1MAPK1MAPTMTORALDH1A1 | |
| SCHEMBL7458020 | 0.77 | MTOR (0.50) | NPSR1MAPK1MAPTMTORCYP1A2 | |
| SCHEMBL28655466 | 0.73 | CUL4A (0.51) | NPSR1MAPK1MTORATR | |
| SCHEMBL28648550 | 0.73 | CUL4A (0.51) | NPSR1MAPK1MTORATR | |
| SCHEMBL30623433 | 0.73 | CUL4A (0.51) | NPSR1MAPK1MTORATR | |
| SCHEMBL30623361 | 0.73 | CUL4A (0.51) | NPSR1MAPK1MTORATR | |
| SCHEMBL28648545 | 0.73 | CUL4A (0.51) | NPSR1MAPK1MTORATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | disclosed |
| US-6599911-B2 | Particularly useful in treating and suppressing human Cytomegalovirus | TULARIK INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030045715-A1 | Arylsulfonic acid salts of pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-03-06 | — | — | US | disclosed |
| EP-1248783-A1 | ARYLSULFONIC ACID SALTS OF PYRIMIDINE-BASED ANTIVIRAL AGENTS | Tularik Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6410726-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2002-06-25 | — | — | US | disclosed |
| US-20020065279-A1 | Useful in treating and suppressing human Cytomegalovirus | AMGEN INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2001051485-A1 | ARYLSULFONIC ACID SALTS OF PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065279-A1 | Useful in treating and suppressing human Cytomegalovirus | TPMT, MGMT, NSUN2 | NPSR1 3104/4885MAPK1 1636/4885MAPT 3595/4885 |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | NPSR1 4258/4885MAPK1 3896/4885MAPT 2656/4885 |
| US-20030045715-A1 | Arylsulfonic acid salts of pyrimidine-based antiviral agents | PNP, TPMT, NSUN2 | NPSR1 1540/4885MAPK1 631/4885MAPT 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.